Navigation Links
TREATMENT OF PRIMARY LIVER CANCER: SARAH STUDY NOW AVAILABLE FOR ALL ELIGIBLE PATIENTS THROUGHOUT FRANCE
Date:6/24/2013

f the ten most-common cancers in the world, with nearly 750,000 cases diagnosed annually, and the third-leading cause of cancer deaths.[3]  It occurs with greatest frequency in regions where viral hepatitis B or C are most often diagnosed, such as in Asia Pacific and Southern Europe.  

Hepatocellular cancer can be cured by surgery, either by resecting the diseased parts of the liver, or by transplantation with a liver from a healthy donor.  These interventions, however, are inappropriate for the great majority of patients, whose survival may range from a few months to two or more years depending largely on the state of their liver at the time of their diagnosis and the extent of tumour invasion.

About Selective Internal Radiation Therapy (SIRT)

SIRT, also known as radioembolization, is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumours.  It is a minimally-invasive treatment, in which millions of radioactive SIR-Spheres microspheres (diameter between 20-60 microns) are infused via a catheter into the liver, where they selectively target liver tumours with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.  

References:

  1. SorAfenib versus Radioembolization in Advanced Hepatocellular carcinoma (SARAH): http://clinicaltrials.gov/ct2/show/NCT01482442.  
  2. Sangro B, Carpanese L, Cianni R et al on behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY). Survival after 90Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation. Hepatology 2011; 54: 868-878.
  3. GLOBOCAN. 
    '/>"/>

SOURCE SARAH trialists
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... TOKYO , July 28, 2014  ImaginAb, ... Roger Crystal , MD as Vice President of ... Global Business Development Product Acquisition & Licensing team at ... developing business strategy and partnerships in the precision medicine ... partner with biotechnology and pharmaceutical companies across the spectrum ...
(Date:7/28/2014)... July 28, 2014   Cardioxyl Pharmaceuticals, Inc. ... demonstrating that CXL-1427, a novel potential treatment for acute ... volunteers. The company has now initiated dosing of hospitalized ... clinical trial designed to further evaluate the drug,s safety ... The Phase I clinical trial evaluated the safety ...
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Sept. 1 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, 2010 ... ... lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:Yongye International Announces RMB 400 Million Revolving Credit Facilities 2Yongye International Announces RMB 400 Million Revolving Credit Facilities 3Yongye International Announces RMB 400 Million Revolving Credit Facilities 4Yongye International Announces RMB 400 Million Revolving Credit Facilities 5Yongye International Announces RMB 400 Million Revolving Credit Facilities 6Yongye International Announces RMB 400 Million Revolving Credit Facilities 7Yongye International Announces RMB 400 Million Revolving Credit Facilities 8French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 2French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 3French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 4French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 5French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 6French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 7
(Date:7/28/2014)... According to a new market ... II-VI, IV-IV, sapphire), Deposition Technology (CVD, MBE, HVPE, ... Application, and Geography-2013-2020", published by MarketsandMarkets, the market ... 12.63% from 2014 to 2020 and reach $104.55 ... tables and 88 figures spread through 342 pages ...
(Date:7/28/2014)... A St. Jude Children’s Research Hospital ... childhood cancer more than doubled their risk of developing ... follow a heart-healthy lifestyle. The results appear in the ... percent of the 1,598 adult survivors of childhood cancer ... for health risk factors like high blood pressure, abdominal ...
(Date:7/28/2014)... Over the years, many adolescents have been forced to ... pain in their knees. A new PhD study involving ... often carries on: , "We can see from the ... ages of 12 and 19 experience problems with pain ... daily knee pain in the front of the knee," ...
(Date:7/28/2014)... SOPHIE has evaluated the relationship between the type ... in Europe. The results show that countries with ... countries with contradictory policies (Eastern Europe), present higher ... health than men. Health inequalities are especially remarkable ... 27% higher risk of having poor health compared ...
(Date:7/28/2014)... Australia (PRWEB) July 28, 2014 What ... a happier lifestyle can often be a struggle that ... channel, psychic and medium, Lynette Leckie-Clark provides simple how-to ... book “The Magic of You.” With inspiring spiritual affirmations ... you can find empowerment, confidence and motivation for everyday ...
Breaking Medicine News(10 mins):Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 2Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 3Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 4Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 2Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 3Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 4Health News:Many people never grow out of their growing pains 2Health News:Gender inequalities in health: A matter of policies 2Health News:Be Empowered to Achieve Happiness from New Book "The Magic of You" 2
... prime minister Mr. Girija Prasad Koirala, which was scheduled to ... health, but his party sources informed that his condition is ... King Gyanendra Thursday evening, was scheduled to be administered the ... Friday, two hours before parliament convenes after four long years. ...
... groups are demanding the government for new and better breast ... National Institute// for Clinical Excellence rejected two new breast cancer ... the patient groups who were campaigning for access to every ... cheaper medicines in clinical trials. The two drugs were docetaxel ...
... eight-year pupil in southwest China's Sichuan province was confirmed ... ministry said Thursday//. ,The girl, surnamed Sun, from ... of fever and pneumonia April 16. She was being ... ,Investigators reported that poultry deaths occurred in ...
... A study by Dutch researchers suggests that eating foods ... down the risk of developing motor neurone disease by ... Utrecht in the Netherlands report their findings in the ... tracked 132 patients who had potential or definite amyotrophic ...
... offered to GPs after negative publicity over the move resulted ... were responsible for NHS deficits. ,The new GP ... increased by 25 percent. BMA's Dr Mary Church defended the ... being as much as ?100,000 was true for GPs in ...
... of asthma symptoms in people with allergic asthma. Dust mites, ... important cause of allergic reactions. //The proteins present in the ... similar to that of asthma. Hence the development of the ... ,Cytos is a Swiss vaccine company which manufactures this vaccine. ...
Cached Medicine News:
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: